Ono Pharmaceutical has been granted a patent for a compound of formula (Id-1-1) for treating disorders related to TREK-1, TREK-2, or both TREK-1 and TREK-2 dysfunction in mammals. The patent also covers pharmaceutical compositions, methods of making the compounds, and kits containing the compounds. GlobalData’s report on Ono Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ono Pharmaceutical, Peptide pharmacophores was a key innovation area identified from patents. Ono Pharmaceutical's grant share as of January 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Compound for treating disorders associated with trek-1 and trek-2 dysfunction
A recently granted patent (Publication Number: US11851428B2) discloses a compound of formula (Id-1-1) along with its various derivatives. The patent claims include the compound itself, as well as its pharmaceutical composition. The compound mentioned in the claims is specified as either N-[2-methyl-4-(trifluoromethoxy)benzyl]-6-(1H-1,2,4-triazol-1-yl)nicotinamide or N-[2-methoxy-4-(trifluoromethoxy)benzyl]-4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzamide, or their pharmaceutically acceptable salts.
Furthermore, the patent also covers a pharmaceutical composition that includes a therapeutically effective amount of the compound mentioned in the claims or its pharmaceutically acceptable salt, along with a pharmaceutically acceptable carrier. This composition is intended for use in the treatment of various conditions or diseases, as outlined in the patent claims. The patent provides protection for the compound and its pharmaceutical composition, ensuring exclusivity for the inventors to commercialize their innovation in the market.
To know more about GlobalData’s detailed insights on Ono Pharmaceutical, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
